Memorial Sloan Kettering Cancer Center shared on X:
“The FDA has approved the immunotherapy drug pembrolizumab (Keytruda) to be given before and after surgery for patients with head and neck squamous cell cancer (HNSCC) in combination with standard therapy.
Dr. Nancy Lee, a radiologist oncologist at MSK, helped design the clinical trial showing that immunotherapy given around surgery could reduce recurrence of some head and neck cancers.
‘This is the first FDA approval in nearly two decades of a treatment for this patient group,’ she says. ‘It will be practice-changing and benefit many people.’
Learn more about Dr. Lee’s research.”